Development of a functional assay to test for homologous recombination in ovarian cancer
Background: PARP inhibitors selectively target homologous recombination (HR) defective cells and show good clinical activity in hereditary breast and ovarian cancer associated with BRCAl12 mutations. A high proportion (up to 50%) of sporadic epithelial ovarian cancers (EOC) could be deficient in HR...
| Main Author: | |
|---|---|
| Published: |
University of Newcastle Upon Tyne
2011
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.577481 |